. 2024 Feb 28;25(5):2798. doi: 10.3390/ijms25052798

Table 1.

Ongoing clinical trials related to HPV⁺OPSCC.

Phase	Trial	Population	Therapy	Objectives	Status
2	NCT03799445	Advanced HPV⁺ HNSCC	Concurrent ipilimumab + nivolumab + RT	Complete response rate Progression free survival Toxicity	Recruiting
2	NCT03383094	Intermediate/high-risk HPV⁺ locoregionally-advanced HNSCC	Concurrent and adjuvant pembrolizumab + RT vs. RT + cisplatin	Progression-free survival Overall survival Toxicity	Recruiting
2	NCT04988074	Advanced HPV⁺OPSCC	Neoadjuvant cemiplimab + TORS/RT +/− chemotherapy	Progression-free survival Quality of life Swallow function Overall survival	Recruiting
2	NCT04867330	HPV⁺OPSCC	Toripalimab + docetaxel/cisplatin	Progression-free survival	Recruiting
3	NCT04116047	Intermediate/high-risk HPV⁺OPSCC	Durvalumab vs. chemoradiotherapy	Overall survival Event-free survival Toxicity Quality of life	Recruiting
2	NCT03410615	Intermediate-risk HPV⁺ locoregionally-advanced OPSCC	Durvalumab + RT + adjuvant Durvalumab vs. Durvalumab + RT + adjuvant Tremelimumab and Durvalumab vs. Cisplatin + RT	Event-free survival Functional assessment Locoregional failure Overall survival	Active, not recruiting
2	NCT03829722	High-risk HPV⁺OPSCC	Concurrent nivolumab + RT + carboplatin	Progression-free survival Overall survival Toxicity	Active, not recruiting
2	NCT03107182	Locoregionally-advanced HPV⁺OPSCC	Nivolumab/Nab-paclitaxel/Carboplatin Induction Chemotherapy followed by Response-stratified Locoregional Therapy	Deep response rate Adverse events Progression-free survival Overall survival	Active, not recruiting
2	NCT03838263	High-risk HPV⁺OPSCC	Neoadjuvant nivolumab + chemoradiotherapy vs. chemoradiotherapy alone	Feasibility assessment Adverse events Objective response rate Overall survival Progression-free survival	Active, not recruiting
2/3	NCT03952585	Early-stage HPV⁺OPSCC	Concurrent reduced-dose RT + either nivolumab or cisplatin	Progression-free survival Quality of life Overall survival	Suspended
3	NCT03811015	Intermediate risk locally-advanced HPV⁺OPSCC	Definitive chemoradiotherapy followed by maintenance nivolumab	Overall survival Progression-free survival	Recruiting

RT = radiotherapy. TORS = transoral robotic surgery